L-Carnitine
β-Thalassemia Intermedia
Shiraz University of Medical SciencesPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the β-Thalassemia Intermedia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sodium 2,2 Dimethylbutyrate Boston University | Phase 2 | B |
Mitapivat Agios Pharmaceuticals, Inc. | Phase 3 | B |
Vit-2763 Twice A Day Vifor (International) Inc. | Phase 2 | B |
Hydroxyurea Shiraz University of Medical Sciences | Phase 2 | B |
Vit-2763 Once A Day Vifor (International) Inc. | Phase 2 | B |
View all 11 →
Same molecule, other indications
L-Carnitine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →